Cochrane · systematic review · CD012967
Alpha‐lipoic acid for diabetic peripheral neuropathy
Baicus, C, Purcarea, A, von Elm, E, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
2
Included studies
NR
No studies 2 · 40%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 2 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy
Population: people with DPN
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in neuropathy symptoms Alpha‐lipoic acid vs placebo | no estimate extracted | 1 study · 330 participants | Moderate Downgraded: risk of bias |
Change in impairment Alpha‐lipoic acid vs placebo | no estimate extracted | 1 study · 245 participants | Low Downgraded: risk of bias, imprecision |
Change in any validated quality of life score Alpha‐lipoic acid vs placebo | no estimate extracted | NR | No studies |
Complications of DPN Alpha‐lipoic acid vs placebo | no estimate extracted | NR | No studies |
Adverse events leading to cessation of treatment Alpha‐lipoic acid vs placebo | RR 1.48 [0.5, 4.35] | 3 studies · 1090 participants | Moderate Downgraded: risk of bias |